Schrödinger (NASDAQ:SDGR) Sets New 12-Month Low - Should You Sell?

Schrödinger, Inc. (NASDAQ:SDGR - Get Free Report)'s share price reached a new 52-week low during trading on Monday . The stock traded as low as $16.60 and last traded at $16.81, with a volume of 122513 shares. The stock had previously closed at $18.03.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SDGR. Piper Sandler reduced their target price on Schrödinger from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. KeyCorp boosted their price objective on Schrödinger from $25.00 to $27.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Schrödinger has an average rating of "Buy" and a consensus target price of $32.29.

Schrödinger Stock Up 27.4 %

The firm has a 50 day moving average of $21.98 and a 200 day moving average of $20.74. The firm has a market cap of $1.79 billion, a PE ratio of -10.47 and a beta of 1.77.

Schrödinger (NASDAQ:SDGR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm had revenue of $88.32 million for the quarter, compared to analysts' expectations of $83.20 million. On average, research analysts anticipate that Schrödinger, Inc. will post -2.37 EPS for the current year.

Remove Ads

Insiders Place Their Bets

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the sale, the chief financial officer now owns 27,544 shares in the company, valued at $599,357.44. This represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 8.60% of the company's stock.

Institutional Trading of Schrödinger

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. boosted its stake in Schrödinger by 60.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company's stock worth $67,718,000 after purchasing an additional 1,319,464 shares during the period. Nikko Asset Management Americas Inc. boosted its position in shares of Schrödinger by 108.7% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 2,464,911 shares of the company's stock valued at $47,499,000 after acquiring an additional 1,283,949 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Schrödinger by 17.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,279,313 shares of the company's stock valued at $43,968,000 after acquiring an additional 334,131 shares in the last quarter. State Street Corp increased its holdings in Schrödinger by 1.8% during the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company's stock worth $39,987,000 after acquiring an additional 38,972 shares during the period. Finally, Lazard Asset Management LLC increased its holdings in Schrödinger by 3.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,700,909 shares of the company's stock worth $32,810,000 after acquiring an additional 58,541 shares during the period. 79.05% of the stock is currently owned by institutional investors.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.